Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MDxHealth ( (MDXH) ) has provided an update.
MDxHealth SA reported a significant financial improvement in its 2025 Interim Report, with revenue increasing by 21% to $50.9 million and gross profit rising by 30% compared to the previous year. Despite a net loss of $16.6 million, the company reduced its operating loss by 54%, indicating a positive trajectory driven by higher revenues and gross profit. The company acknowledges ongoing net losses and cash outflows but remains optimistic about its ability to continue operations, citing sufficient cash reserves and potential access to additional funding.
The most recent analyst rating on (MDXH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s strong revenue growth and technical momentum are offset by financial instability and valuation concerns. The company’s strategic positioning in prostate cancer diagnostics is promising, but profitability and cash flow challenges need resolution for a higher score.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA operates in the healthcare industry, focusing on the commercialization of diagnostic tests and related products. The company is known for its tissue-based tests, including Confirm mdx, Select mdx, Resolve mdx, Monitor mdx, and Genomic Prostate Score (GPS) tests, which are primarily targeted at the healthcare sector.
Average Trading Volume: 79,203
Technical Sentiment Signal: Hold
Current Market Cap: $142.1M
For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.